Prothena development chief resigns: what it means for Prothena stock

Published on 10/13/2026 at 07:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chad Swanson's resignation took effect October 9, 2026, with a partner program in his new role. For Prothena stock, Q2 revenue was USD 1.01 million.

Key points in brief

Prothena's chief development officer resigned effective October 9, 2026.
The departing executive moved to a strategic partner and will lead a partnered program.
Second-quarter 2026 revenue was USD 1.01 million, while diluted earnings per share were minus USD 0.36.
Prothena is listed on the Nasdaq Global Select Market under ticker PRTA.
The next earnings report is scheduled for October 29, 2026.

PRTA, IE00B91XRN20, Illustration mit AI erstellt.

Prothena Corporation plc (ISIN IE00B91XRN20) disclosed on October 2, 2026, that Chief Development Officer Chad J. Swanson would resign effective October 9. According to the SEC filing, Swanson moved to a strategic partner, where he would assume leadership of a program partnered with Prothena.

Three dated developments

On August 6, 2026, Prothena reported second-quarter revenue of USD 1.01 million and diluted earnings per share of minus USD 0.36, compared with a consensus loss of USD 0.39 per share, according to InsiderTrades.com. On October 2, Prothena disclosed Swanson's departure, and on October 8, major shareholder William Scully bought 90,000 shares at an average USD 8.57, according to InsiderTrades.com.

What does the change mean?

The immediate issue is continuity rather than a disclosed pipeline reduction. Swanson's next role remains tied to a partnered program, so the transition keeps a collaboration link in place while moving day-to-day development leadership outside Prothena.

The latest reported quarter shows why execution matters. Revenue of USD 1.01 million was higher than the USD 0.42 million consensus cited by MarketBeat, while the company still posted a quarterly loss. That combination leaves clinical progress and partnership execution as the central operating variables.

Next reporting date

Prothena's next earnings report is scheduled for October 29, 2026, according to TradingView. The date gives investors a defined checkpoint for updates on the pipeline and the leadership transition.

Pipeline and listing details

Prothena is a clinical-stage biotechnology company focused on therapies for diseases caused by protein dysregulation. Its reported second-quarter cash balance was USD 288.2 million, while operating cash flow was negative USD 25.0 million, providing financial context for a development pipeline that still depends on clinical and partnership milestones.

Prothena's ordinary shares trade under ticker PRTA on the Nasdaq Global Select Market. The further course of trading is shown by the continuously updated real-time quote of Prothena stock.